Core C Clinical Trials Core: The function of Core C is to facilitate the translation of laboratory findings into the necessary clinical and correlative studies. This Clinical Trials Core provides the support and resources for activation, conduct and completion of the clinical trials or clinically-related aspects of each of the projects. This Core will provide the infrastructure so that concepts emanating from the projects can be evaluated for translational suitability, formulated into appropriate clinical protocols that will be carried out with the appropriate regulatory oversight, safety and collection of clinical data. This core is a necessary and vital component of the SARC Sarcoma SPORE and will streamline and standardize interaction with the clinical trial infrastructure of forty sarcoma clinical trials centers across the United States. The success of SARC is significantly based upon an outstanding record of accomplishment of designing, conducting and analyzing clinical trials in patients with sarcoma. SARC Clinical Trials Core leadership under the direction of Laurence Baker is experienced in facilitating multi-center research.

Public Health Relevance

Currently there are limited programs that have the capabilities to provide the infrastructure for collaboration on clinical trial research for sarcoma. Because sarcoma is a relatively uncommon disease and that it occurs across the human like span, this clinical trial Core will provide the infrastructure to facilitate the conduct of clinical research to identify new beneficial treatment options for patients with sarcoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA168512-02
Application #
8561224
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
2
Fiscal Year
2013
Total Cost
$167,606
Indirect Cost
$9,487
Name
Sarc
Department
Type
DUNS #
186146911
City
Ann Arbor
State
MI
Country
United States
Zip Code
48106
Choy, Edwin; Ballman, Karla; Chen, James et al. (2018) SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. Sarcoma 2018:2068517
Yu, Peter Y; Lopez, Gonzalo; Braggio, Danielle et al. (2018) miR-133a function in the pathogenesis of dedifferentiated liposarcoma. Cancer Cell Int 18:89
Ignatius, Myron S; Hayes, Madeline N; Moore, Finola E et al. (2018) tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish. Elife 7:
Hawkins, Allegra G; Basrur, Venkatesha; da Veiga Leprevost, Felipe et al. (2018) The Ewing Sarcoma Secretome and Its Response to Activation of Wnt/beta-catenin Signaling. Mol Cell Proteomics 17:901-912
Lopez, Gonzalo; Pollock, Raphael E (2017) Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors. Methods Mol Biol 1510:365-374
Tang, Fan; Choy, Edwin; Tu, Chongqi et al. (2017) Therapeutic applications of histone deacetylase inhibitors in sarcoma. Cancer Treat Rev 59:33-45
Chen, James L; David, Jason; Cook-Spaeth, Douglas et al. (2017) Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease. Mol Cancer Res 15:26-34
Haak, Andrew J; Appleton, Kathryn M; Lisabeth, Erika M et al. (2017) Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma. Mol Cancer Ther 16:193-204
Hayashi, Masanori; Zhu, Peixuan; McCarty, Gregory et al. (2017) Size-based detection of sarcoma circulating tumor cells and cell clusters. Oncotarget 8:78965-78977
Smith, Steven C; Gooding, William E; Elkins, Matthew et al. (2017) Solitary Fibrous Tumors of the Head and Neck: A Multi-Institutional Clinicopathologic Study. Am J Surg Pathol 41:1642-1656

Showing the most recent 10 out of 111 publications